Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lucid Diagnostics Inc.LUCD · Entity 6375 | Director | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lucid Diagnostics Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 320,460 |
Reported balance
After 2026-02-20 transaction · row 1
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 123,000 · Balance 320,460 F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 24, 2026 23:48 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 123,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000074 · form4.xml · nonDerivative · entry 1 SOKOLOV JACQUE J · CIK 0001282803 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,460 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:36 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantCommon Stock | 112,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003202 · form4.xml · nonDerivative · entry 1 SOKOLOV JACQUE J · CIK 0001282803 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,460 F1 · shares: Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:37 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001062993-24-004273 · form4.xml · derivative · entry 1 SOKOLOV JACQUE J · CIK 0001282803 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2034-02-22 F1 · derivative.exercise_date: One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:40 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001062993-23-002039 · form4.xml · derivative · entry 1 SOKOLOV JACQUE J · CIK 0001282803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common stock · 175,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 16:09 UTC | Lucid Diagnostics Inc. LUCD · Entity 6375 | GrantEmployee stock option (right to buy) · Derivative | 59,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001062993-22-005542 · form4.xml · derivative · entry 1 SOKOLOV JACQUE J · CIK 0001282803 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common stock · 59,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: The option vests in 12 quarterly installments, with first installment vesting March 31, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.